BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

865 related articles for article (PubMed ID: 35177220)

  • 21. Angiogenic profiling in HELLP syndrome cases with or without hypertension and proteinuria.
    Trottmann F; Baumann M; Amylidi-Mohr S; Surbek D; Risch L; Mosimann B; Raio L
    Eur J Obstet Gynecol Reprod Biol; 2019 Dec; 243():93-96. PubMed ID: 31678761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fetal-origin cells in maternal circulation correlate with placental dysfunction, fetal sex, and severe hypertension during pregnancy.
    Fjeldstad HE; Jacobsen DP; Johnsen GM; Sugulle M; Chae A; Kanaan SB; Gammill HS; Staff AC
    J Reprod Immunol; 2024 Mar; 162():104206. PubMed ID: 38309014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor.
    Espinoza J; Romero R; Nien JK; Gomez R; Kusanovic JP; Gonçalves LF; Medina L; Edwin S; Hassan S; Carstens M; Gonzalez R
    Am J Obstet Gynecol; 2007 Apr; 196(4):326.e1-13. PubMed ID: 17403407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.
    Noori M; Donald AE; Angelakopoulou A; Hingorani AD; Williams DJ
    Circulation; 2010 Aug; 122(5):478-87. PubMed ID: 20644016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic hypertension and superimposed preeclampsia: screening and diagnosis.
    Kametas NA; Nzelu D; Nicolaides KH
    Am J Obstet Gynecol; 2022 Feb; 226(2S):S1182-S1195. PubMed ID: 35177217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders.
    Rana S; Burke SD; Karumanchi SA
    Am J Obstet Gynecol; 2022 Feb; 226(2S):S1019-S1034. PubMed ID: 33096092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preeclampsia at term: evidence of disease heterogeneity based on the profile of circulating cytokines and angiogenic factors.
    Chaiworapongsa T; Romero R; Gomez-Lopez N; Suksai M; Gallo DM; Jung E; Berry SM; Awonuga A; Tarca AL; Bryant DR
    Am J Obstet Gynecol; 2024 Apr; 230(4):450.e1-450.e18. PubMed ID: 37806612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia--a step forward but not the definitive answer.
    Foidart JM; Schaaps JP; Chantraine F; Munaut C; Lorquet S
    J Reprod Immunol; 2009 Nov; 82(2):106-11. PubMed ID: 19853925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First trimester serum angiogenic and anti-angiogenic factors in women with chronic hypertension for the prediction of preeclampsia.
    Nzelu D; Biris D; Karampitsakos T; Nicolaides KK; Kametas NA
    Am J Obstet Gynecol; 2020 Apr; 222(4):374.e1-374.e9. PubMed ID: 31705883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of preeclampsia throughout gestation with maternal characteristics and biophysical and biochemical markers: a longitudinal study.
    Tarca AL; Taran A; Romero R; Jung E; Paredes C; Bhatti G; Ghita C; Chaiworapongsa T; Than NG; Hsu CD
    Am J Obstet Gynecol; 2022 Jan; 226(1):126.e1-126.e22. PubMed ID: 34998477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiogenic markers and their longitudinal change for predicting adverse outcomes in pregnant women with chronic hypertension.
    Binder J; Kalafat E; Palmrich P; Pateisky P; Khalil A
    Am J Obstet Gynecol; 2021 Sep; 225(3):305.e1-305.e14. PubMed ID: 33812812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome.
    Stepan H; Hund M; Gencay M; Denk B; Dinkel C; Kaminski WE; Wieloch P; Semus B; Meloth T; Dröge LA; Verlohren S
    Hypertens Pregnancy; 2016 Aug; 35(3):295-305. PubMed ID: 27028698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Usefulness of the sFlt-1/PlGF (Soluble fms-Like Tyrosine Kinase-1/Placental Growth Factor) Ratio in Diagnosis or Misdiagnosis in Women With Clinical Diagnosis of Preeclampsia.
    Leaños-Miranda A; Graciela Nolasco-Leaños A; Ismael Carrillo-Juárez R; José Molina-Pérez C; Janet Sillas-Pardo L; Manuel Jiménez-Trejo L; Isordia-Salas I; Leticia Ramírez-Valenzuela K
    Hypertension; 2020 Sep; 76(3):892-900. PubMed ID: 32713272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pre-eclampsia screening in first and second trimester].
    Kang A; Struben H
    Ther Umsch; 2008 Nov; 65(11):663-6. PubMed ID: 18979429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiogenic Factors and Long-Term Cardiovascular Risk in Women That Developed Preeclampsia During Pregnancy.
    Garrido-Gimenez C; Mendoza M; Cruz-Lemini M; Galian-Gay L; Sanchez-Garcia O; Granato C; Rodriguez-Sureda V; Rodriguez-Palomares J; Carreras-Moratonas E; Cabero-Roura L; Llurba E; Alijotas-Reig J
    Hypertension; 2020 Dec; 76(6):1808-1816. PubMed ID: 33012203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between adverse pregnancy outcome and imbalance in angiogenic regulators and oxidative stress biomarkers in gestational hypertension and preeclampsia.
    Turpin CA; Sakyi SA; Owiredu WK; Ephraim RK; Anto EO
    BMC Pregnancy Childbirth; 2015 Aug; 15():189. PubMed ID: 26303772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.
    Maynard SE; Min JY; Merchan J; Lim KH; Li J; Mondal S; Libermann TA; Morgan JP; Sellke FW; Stillman IE; Epstein FH; Sukhatme VP; Karumanchi SA
    J Clin Invest; 2003 Mar; 111(5):649-58. PubMed ID: 12618519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of sFlt-1/PlGF ratio and feto-maternal Doppler for the prediction of adverse perinatal outcome in late-onset pre-eclampsia.
    Graupner O; Karge A; Flechsenhar S; Seiler A; Haller B; Ortiz JU; Lobmaier SM; Axt-Fliedner R; Enzensberger C; Abel K; Kuschel B
    Arch Gynecol Obstet; 2020 Feb; 301(2):375-385. PubMed ID: 31734756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of the soluble fms-like tyrosine kinase-1 to placental growth factor ratio in pregnancies complicated by fetal growth restriction.
    Herraiz I; Dröge LA; Gómez-Montes E; Henrich W; Galindo A; Verlohren S
    Obstet Gynecol; 2014 Aug; 124(2 Pt 1):265-273. PubMed ID: 25004342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Similar Pro- and Antiangiogenic Profiles Close to Delivery in Different Clinical Presentations of Two Pregnancy Syndromes: Preeclampsia and Fetal Growth Restriction.
    Dymara-Konopka W; Laskowska M; Grywalska E; Hymos A; Błażewicz A; Leszczyńska-Gorzelak B
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.